Literature DB >> 18953428

Involvement of epigenetic mechanisms in the regulation of secreted phospholipase A2 expressions in Jurkat leukemia cells.

Mario Menschikowski1, Albert Hagelgans, Heike Kostka, Graeme Eisenhofer, Gabriele Siegert.   

Abstract

Epigenetic changes provide a frequent mechanism for transcriptional silencing of genes in cancer cells. We previously established that epigenetic mechanisms are important for control of group IIA phospholipase A(2) (PLA2G2A) gene transcription in human DU-145 prostate cells. In this study, we analyzed the involvement of such mechanisms in the regulation of five sPLA(2) isozymes and the M-type receptor of sPLA(2) (sPLA(2)-R) in human leukemic Jurkat cells. These cells constitutively expressed sPLA(2)-IB, sPLA(2)-III, sPLA(2)-X, and sPLA(2)-R but not sPLA(2)-IIA and sPLA(2)-V. Transcription of sPLA(2)-IIA and sPLA(2)-V was, however, detected after exposure of cells to the DNA demethylating agent, 5-aza-2'-deoxycytidine (5-aza-dC). Expression of sPLA(2)-IIA was further enhanced by additional exposure to interferon-gamma and blocked by inhibitors of specificity protein 1, nuclear factor kappaB, and Janus kinase/signal transducer and activator of transcription-dependent pathways. Sequence analysis and methylation-specific polymerase chain reaction of bisulfite-modified genomic DNA revealed two 5'-CpG sites (-111 and -82) in the sPLA(2)-IIA proximal promoter that were demethylated after 5-aza-dC treatment. These sites may be involved in the DNA binding of specificity protein 1 and other transcription factors. Similar findings after treatment of human U937 leukemia cells with 5-aza-dC indicate that this mechanism of PLA2G2A gene silencing is not restricted to Jurkat and DU-145 cells. These data establish that regulation of sPLA(2)-IIA and sPLA(2)-V in Jurkat and other cells involves epigenetic silencing by DNA hypermethylation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18953428      PMCID: PMC2570595          DOI: 10.1593/neo.08640

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  53 in total

1.  Object-oriented transcription factors database (ooTFD).

Authors:  D Ghosh
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins.

Authors:  E Valentin; G Lambeau
Journal:  Biochim Biophys Acta       Date:  2000-10-31

Review 3.  Transcriptional regulation of cellular ageing by the CCAAT box-binding factor CBF/NF-Y.

Authors:  Koozi Matuoka; Kuang Yu Chen
Journal:  Ageing Res Rev       Date:  2002-09       Impact factor: 10.895

Review 4.  Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?

Authors:  Mario Menschikowski; Albert Hagelgans; Gabriele Siegert
Journal:  Prostaglandins Other Lipid Mediat       Date:  2005-12-27       Impact factor: 3.072

5.  Implication of three isoforms of PLA(2) in human T-cell proliferation.

Authors:  Christian Tessier; Aziz Hichami; Naim Akhtar Khan
Journal:  FEBS Lett       Date:  2002-06-05       Impact factor: 4.124

6.  Human calcium-independent phospholipase A2 mediates lymphocyte proliferation.

Authors:  A K Roshak; E A Capper; C Stevenson; C Eichman; L A Marshall
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

Review 7.  Transcriptional regulation of inflammatory secreted phospholipases A(2).

Authors:  M Andreani; J L Olivier; F Berenbaum; M Raymondjean; G Béréziat
Journal:  Biochim Biophys Acta       Date:  2000-10-31

Review 8.  The expanding superfamily of phospholipase A(2) enzymes: classification and characterization.

Authors:  D A Six; E A Dennis
Journal:  Biochim Biophys Acta       Date:  2000-10-31

9.  Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.

Authors:  Jiazhong Jiang; Blake Lee Neubauer; Jeremy R Graff; Marcio Chedid; James E Thomas; Neal W Roehm; Shaobo Zhang; George J Eckert; Michael O Koch; John N Eble; Liang Cheng
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

10.  Identification and resolution of artifacts in bisulfite sequencing.

Authors:  Peter M Warnecke; Clare Stirzaker; Jenny Song; Christoph Grunau; John R Melki; Susan J Clark
Journal:  Methods       Date:  2002-06       Impact factor: 3.608

View more
  6 in total

1.  Epigenetic control of group V phospholipase A2 expression in human malignant cells.

Authors:  Mario Menschikowski; Albert Hagelgans; Brit Nacke; Carsten Jandeck; Olga A Mareninova; Liana Asatryan; Gabriele Siegert
Journal:  Tumour Biol       Date:  2015-12-29

2.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

3.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

4.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

5.  Plasma levels of phospholipase A2-IIA in patients with different types of malignancies: prognosis and association with inflammatory and coagulation biomarkers.

Authors:  Mario Menschikowski; Albert Hagelgans; Ulrich Schuler; Susanne Froeschke; Andrea Rosner; Gabriele Siegert
Journal:  Pathol Oncol Res       Date:  2013-06-01       Impact factor: 3.201

6.  Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells.

Authors:  Mario Menschikowski; Albert Hagelgans; Brit Nacke; Carsten Jandeck; Olga Sukocheva; Gabriele Siegert
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.